Synergistic anti-hypernociceptive interaction between morphine and JM-20 in neuropathic rats. Mechanistic insights into metabolism, transport, and safety.

This study evaluated the anti-hypernociceptive interaction between morphine and the neuroprotective compound 3-ethoxycarbonyl-2-methyl-4-(2-nitrophenyl)-4,11-dihydro-1H-pyrido[2,3-b][1,5]benzodiazepine (JM-20) in neuropathic rats. Single and repeated co-administration of both drugs was assessed using the chronic constriction injury (CCI) model, via subcutaneous and oral routes. Isobolographic analysis was performed to determine the nature of the pharmacological interaction. In addition, in silico pharmacokinetic and toxicological profiling was conducted, and JM-20's effects on human UDP-glucuronosyltransferase (UGT) and cytochrome P450 (CYP) enzyme systems were evaluated in vitro. Morphine, JM-20, and their 1:1 fixed-ratio combinations significantly attenuated mechanical hypersensitivity in a dose-dependent manner. The observed ED50 for the combination (2.15 ± 0.07 mg/kg) was significantly lower than the theoretical additive ED50 (8.05 ± 0.58 mg/kg), indicating a synergistic interaction. Repeated morphine administration led to tolerance, while the morphine:JM-20 combination maintained efficacy for 14 days and prevented morphine-induced facilitation of neuropathic hypersensitivity. JM-20 did not alter UGT activity, suggesting no interference with morphine glucuronidation or active metabolite formation. However, JM-20 strongly inhibited CYP3A4 and other major CYP isoforms (1A, 2C9, 2D6, 2A6), potentially relevant for interactions with co-administered drugs, though not with morphine. JM-20 may also inhibit P-glycoprotein, possibly enhancing morphine's central bioavailability. In silico and in vitro analyses indicated a potential risk of cardiotoxicity and hepatotoxicity. Overall, JM-20 enhances morphine analgesia in neuropathic pain, but further in vivo studies are required to evaluate the long-term safety of this combination.